Yamamoto Mariko, Nakadate Hisaya, Iguchi Umefumi, Masuda Hiroshi, Sakai Hirokazu, Ishiguro Akira
Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Japan.
Rinsho Ketsueki. 2013 Mar;54(3):300-4.
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid cyst in a follow-up CT scan. He underwent marsupialization of the cyst under the continuous infusion of rFIX. FIX levels were examined in our hospital and the rFIX infusion rate was adjusted in an attempt to keep FIX levels above 90% intraoperatively, and 70% until his 7th post-operative day. We studied the pharmacokinetic profile of rFIX and found a half-time of 25 hours and mean in vivo recovery of 0.69 IU/dl/IU/kg. Reconstituted rFIX also retained at least 95% activity after 72 hours at room temperature. This is the first report of the perioperative management of a child undergoing a neurosurgical procedure under the continuous infusion of rFIX in Japan. Further studies are required before the routine use of this product for continuous infusion.
本报告描述了在持续输注重组因子IX(rFIX)的情况下神经外科手术的成功管理。一名1岁重度B型血友病男孩在颅内出血后接受了rFIX预防性治疗。在后续的CT扫描中,我们发现了一个蛛网膜囊肿增大。他在持续输注rFIX的情况下接受了囊肿开窗术。在我院检测了FIX水平,并调整了rFIX输注速率,试图在术中使FIX水平保持在90%以上,术后第7天前保持在70%以上。我们研究了rFIX的药代动力学特征,发现半衰期为25小时,体内平均回收率为0.69 IU/dl/IU/kg。复溶后的rFIX在室温下放置72小时后也至少保留95%的活性。这是日本首例关于在持续输注rFIX的情况下对儿童进行神经外科手术围手术期管理的报告。在将该产品常规用于持续输注之前,还需要进一步研究。